Trial Profile
Study of 90Y-Ibritumomab tiuxetan in the older population with non-hodgkin lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2017
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 03 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology